PD-L1 expression in metastatic colorectal carcinoma

Krsteska, Blagica and Filipovski, Vanja and Kubelka-Sabit, Katerina and Jasar, Dzengis and Bogdanovska Todorovska, Magdalena and Velickova, Nevenka (2024) PD-L1 expression in metastatic colorectal carcinoma. Archive of Oncology, 30 (1S). p. 30. ISSN 0354-7310 eISSN: 1450-9520

[thumbnail of Krsteska, B. PD-L1 expression in metastatic colorectal carcinoma.pdf] Text
Krsteska, B. PD-L1 expression in metastatic colorectal carcinoma.pdf

Download (2MB)

Abstract

Objective: Programmed cell death ligand-1 (PD-L1) expression in colorectal cancer and its prognostic role in metastatic colorectal carcinoma (mCRC) is not well established. In our study we aim to evaluate the expression of PD-L1 in mCRC and its correlation with the clinicopathological characteristics in these patients.
Introduction: The treatment of metastatic colorectal carcinoma (mCRC) has been improved over the recent years mostly due to molecular classification and new technologies for personalized therapy. PD-L1 is the key inhibitor of the cytotoxic immune response and causes rapid tumor progression with poor prognosis.
Materials and methods: Diagnosed 75 cases of mCRC at Clinical Hospital Acibadem – Sistina were evaluated for PD-L1 expression using clone SP263 in tissue microarray. The expression was evaluated by different cut-offs of >1%, >10%, >50% of tumor cells.
Results: PD-L1 was evaluated positive in 17 cases of mCRC (26,6%). More than a half of positive cases (10) showed cut off >1%. Seventeen percent of positive cases showed cut off >10% and all of them were located in rectosigmoid colon with stage IIIB and IIIC. Three cases were evaluated with a cut off >50% all of them G3 mCRC, stage IIIC and IVA, of which 2 cases were in right colon associated with BRAF mutations.
Conclusion: Expression od PD-L1 was found in almost one third of the cases. A higher cut off was correlated with higher grade, high pathological stage and BRAF mutation. This suggests that mCRC with high PD-L1 expression may show a survival advantage with immune checkpoint inhibitors therapy.

Item Type: Article
Subjects: Medical and Health Sciences > Basic medicine
Medical and Health Sciences > Clinical medicine
Divisions: Faculty of Medical Science
Depositing User: Nevenka Velickova
Date Deposited: 03 Jun 2024 08:44
Last Modified: 03 Jun 2024 08:44
URI: https://eprints.ugd.edu.mk/id/eprint/34199

Actions (login required)

View Item View Item